[vc_row][vc_column][vc_column_text]Immunotherapies harness the natural power of the immune system to fight the tumor and is fundamentally changing how we treat cancer.
In this edition of Guided By Science, we explore the field of intratumoral immunotherapy, a new approach that is taking the fight directly to the tumor.
What is Intratumoral Immunotherapy?
Most of us are familiar with oral tablets and intravenous delivery. Unlike these systemic approaches, intratumoral immunotherapies are applied directly to the tumor. The advantage of intratumoral therapy is that it can stimulate the immune system to attack cancer while reducing the toxicities associated with systemic approaches. (Furthermore, the local aspect of the immune reaction within the tumor would be expected to reduce systemic toxicity, analogous to the use of isolated limb perfusion compared to systemic drug delivery.)[/vc_column_text][vc_single_image image=”6988″ img_size=”full”][vc_column_text]
Case Study: ImmunoPulse® IL-12
ImmunoPulse® IL-12 is an intratumoral immunotherapy being developed by OncoSec Medical (NASDAQ: ONCS). OncoSec’s treatment delivers DNA IL-12 directly into tumor cells. This local treatment is designed to prime the immune system to target and eliminate cancer.[/vc_column_text][/vc_column][/vc_row]